Poseida Therapeutics (NASDAQ:PSTX) shareholders have endured a 55% loss from investing in the stock a year ago

This post was originally published on this site

Poseida Therapeutics wasn’t profitable in the last twelve months, it is unlikely we’ll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next …